BUY GHRP-6 (10 MG/VIAL – 1 VIAL) ONLINE
Main Product Description
GHRP-6 is a synthetic peptide described in the supplied product information as a growth hormone-releasing peptide structurally related to GHRP-2. It is supplied as a 10 mg lyophilised powder per vial and is specifically identified as a research-use-only product rather than an authorised therapeutic medicine.
GHRP-6 is associated with regulation of growth hormone secretion through mechanisms involving the endocrine pathways that control pituitary growth hormone release. The supplied information describes GHRP-6 as capable of stimulating the pituitary gland to release growth hormone and notes that its biological activity differs in certain respects from GHRP-2, particularly regarding effects on appetite.
Product Specifications
- Product: GHRP-6
- Unit size: 10 mg per vial
- Sequence: H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
- Molecular formula supplied: H56N12O6
- Molecular weight: 873.01 g/mol
- CAS number: 87616-84-0
- Physical state: Lyophilised powder
- Route supplied: Injection
- Market status: Research use only
- Manufacturer: Hilma Biocare
- Distributor: Rein Farmacie, Belgium
- Storage: 2–8°C; do not freeze; protect from direct sunlight
Biological Background
Growth hormone secretion is regulated by a complex interaction of hypothalamic and pituitary signals. Growth hormone-releasing hormone (GHRH) stimulates growth hormone secretion, while somatostatin inhibits it. Peptides in the GHRP family are investigated for their ability to influence this regulatory system.
The supplied information describes GHRP-6 as a growth hormone-releasing peptide and compares it structurally with GHRP-2. It also states that GHRP-6 can influence appetite in some individuals, distinguishing it from the appetite profile described for GHRP-2.
Growth Hormone Pathway
The source describes GHRP-6 as stimulating growth hormone release from the pituitary gland. Growth hormone subsequently participates in signalling involving insulin-like growth factor-1 (IGF-1), which is produced in multiple tissues, including the liver.
Growth hormone and IGF-1 are involved in numerous physiological processes, including tissue growth, metabolism and development. Research into growth hormone-releasing peptides has therefore examined their potential effects on the growth hormone/IGF-1 axis.
The supplied information makes additional claims involving muscle growth, strength, fat reduction, recovery, sleep, bone strength, inflammation, energy and anti-ageing effects. These claims have not been established as guaranteed therapeutic outcomes from the product information provided and should therefore not be presented as proven clinical benefits.
Appetite and Ghrelin-Related Activity
One of the characteristics highlighted in the supplied information is an increase in appetite following GHRP-6 administration in some individuals. The source associates this effect with ghrelin-related signalling.
Ghrelin is a naturally occurring hormone produced primarily in the gastrointestinal tract and is involved in regulation of hunger and energy balance. The relationship between GHRP-6 and appetite is therefore an area of interest in peptide and endocrine research.
Although the supplied source discusses GHRP-6 in relation to cachexia, eating disorders and obesity, it does not provide sufficient information to establish these as approved therapeutic indications for this research product.
Research into Muscle and Metabolic Effects
The supplied material describes GHRP-6 as being investigated for potential effects on growth hormone, IGF-1, muscle tissue and metabolism. It also discusses possible effects on recovery and body composition.
These statements should be distinguished from established clinical evidence. The product is explicitly identified as research use only, and the supplied information does not provide a verified marketing authorisation, approved therapeutic indication or comprehensive clinical safety profile.
Combination Research
The source discusses combining GHRP-6 with other peptides and thyroid hormone preparations, including CJC-1295 and T3. These combinations are described in the supplied material as potentially influencing growth hormone signalling.
Such combinations have not been presented here as recommended treatment protocols. Combining biologically active peptides or thyroid hormones can alter endocrine function and may introduce additional safety risks.
Administration Information
The supplied source states that GHRP-6 has been investigated through subcutaneous or intramuscular administration and describes administration in relation to meals.
It also provides experimental dosing schedules. Because the product is identified as research use only, these experimental dosing instructions are not reproduced as human treatment recommendations.
The product should not be marketed as an approved therapy for muscle growth, fat loss, anti-ageing, obesity, cachexia or growth hormone deficiency.
Possible Side Effects
The supplied information identifies several possible effects associated with GHRP-6:
- Increased hunger
- Dizziness
- Headache
- Joint pain
- Rare lactation
- Potential worsening of gynaecomastia in susceptible individuals
The source associates some reproductive effects with possible changes in prolactin.
The supplied information does not establish a complete clinical safety profile. Consequently, additional adverse effects have not been invented or attributed to the product.
Research Status
The supplied product information explicitly identifies GHRP-6 as “Research use only.” This distinction should be maintained throughout product documentation.
No EU marketing authorisation, national medicinal-product authorisation or approved therapeutic indication was supplied. Therefore, GHRP-6 should not be represented as an authorised medicine for human treatment.
Storage and Handling
The supplied storage requirements are:
- Store at 2–8°C
- Do not freeze
- Protect from direct sunlight
GHRP-6 is supplied as a lyophilised powder. Appropriate laboratory handling and storage procedures should be followed in accordance with the manufacturer’s technical information.
Manufacturer and Distribution
Manufactured by: Hilma Biocare
Distributed by: Rein Farmacie, Belgium
The supplied information does not provide a certificate of analysis, batch-specific testing information or regulatory approval documentation.
Important Research Notice
GHRP-6 is identified as a research-use-only peptide. The biological mechanisms and research claims described above should not be interpreted as proof of therapeutic efficacy or safety in humans.
This product information is based on the source material supplied and does not constitute medical advice, a therapeutic recommendation or instructions for human administration.
